Viatris Inc.

Viatris Inc. is an American global pharmaceutical company formed in November 2020 through the combination of Mylan N.V. and Pfizer's Upjohn Business, producing and distributing generic, branded, and complex medicines across more than 165 countries and territories. With approximately 30,000 employees, 27 manufacturing sites, and a portfolio of more than 1,400 approved molecules, Viatris supplies medicines to roughly one billion patients annually — making it one of the largest pharmaceutical companies in the world by volume, if not by market capitalisation.

This is a story about a company that spent its first five years unwinding the consequences of its own creation. The 2020 merger was massive and messy: it saddled Viatris with roughly $25 billion in debt, layered Mylan's sprawling generic manufacturing network on top of Pfizer's off-patent brand portfolio, and left the combined entity with revenue that began declining almost immediately as legacy products lost exclusivity and management raced to divest non-core businesses. Between 2021 and 2025, Viatris sold its biosimilars portfolio to Biocon Biologics, its OTC business to Cooper Consumer Health, its women's healthcare business to Insud Pharma, and its API manufacturing operations in India — shrinking revenue from $17.9 billion to $14.3 billion in the process.

The file turns on a single question: whether Viatris has finally finished shrinking, and whether the pipeline it has been building — anchored by two Phase III innovative assets, a handful of 505(b)(2) products approaching launch, and a rejuvenated commercial presence in Greater China — represents the beginning of something durable or merely a pause between waves of erosion.